US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cross Timbers Royalty

10.09

+0.06000.60%

Post-market: 10.090.00000.00%19:23 EDT

Volume:68.41K

Turnover:694.31K

Market Cap:60.54M

PE:10.14

High:10.38

Open:10.19

Low:10.00

Close:10.03

Loading ...

Overview Company News Filings

Press Release: CROSS TIMBERS ROYALTY TRUST DECLARES MARCH CASH DISTRIBUTION

AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer

SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Press Release: MCCOY GLOBAL ANNOUNCES FOURTH QUARTER AND YEAR END 2024 RESULTS AND INCREASE TO ITS QUARTERLY DIVIDEND

Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results

Press Release: Robotic Telesurgery Data from Collaboration with Corewell Health(TM) Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

CROSS TIMBERS ROYALTY TRUST DECLARES FEBRUARY CASH DISTRIBUTION

AGNC Investment Corp. (AGNC): Among the Best Stocks That Pay Monthly Dividends in 2025

NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry

Biocurious: EBR Systems is on a ‘glide path’ to FDA approval for its novel heart device

CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi

Is AGNC Investment Corp. (AGNC) the Best Monthly Dividend Stock to Buy Right Now?

Enact Mortgage Insurance Enters into Two Forward XOL Reinsurance Transactions as Part of its Diversified Credit Risk Transfer Program

AGNC Investment Corp. (AGNC): Why You Should Invest In This Extreme Dividend Stock Now

Analysts’ Opinions Are Mixed on These Real Estate Stocks: Aena SA (GB:0R4Y), Assura plc (GB:AGR) and Impact Healthcare REIT (GB:CRT)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CRT/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRT\",,,,,undefined,":{"symbol":"CRT","market":"US","secType":"STK","nameCN":"Cross Timbers Royalty","latestPrice":10.09,"timestamp":1749844800000,"preClose":10.03,"halted":0,"volume":68405,"hourTrading":{"tag":"盘后","latestPrice":10.09,"preClose":10.09,"latestTime":"19:23 EDT","volume":103,"amount":1042.77,"timestamp":1749856983658},"delay":0,"floatShares":5999764,"shares":6000000,"eps":0.994757,"marketStatus":"Market Closed","change":0.06,"latestTime":"06-13 16:00:00 EDT","open":10.19,"high":10.3796,"low":10,"amount":694313.554605,"amplitude":0.037846,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.994757,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":699253200000,"exchange":"NYSE","adjPreClose":10.03,"dividendRate":0.098588,"preHourTrading":{"tag":"盘前","latestPrice":10.39,"preClose":10.0879,"latestTime":"08:36 EDT","volume":54,"amount":560.890008,"timestamp":1749818176516},"postHourTrading":{"tag":"盘后","latestPrice":10.09,"preClose":10.09,"latestTime":"19:23 EDT","volume":103,"amount":1042.77,"timestamp":1749856983658},"volumeRatio":3.7880298084171793},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRT\",,,,,undefined,":{"symbol":"CRT","floatShares":5999764,"roa":"92.98%","roe":"240.32%","lyrEps":0.946303,"volumeRatio":3.7880298084171793,"shares":6000000,"dividePrice":0.994757,"high":10.3796,"amplitude":0.037846,"preClose":10.03,"low":10,"week52Low":8.8801,"pbRate":"25.80","psRate":"8.86","week52High":13.3119,"institutionHeld":0.0264,"latestPrice":10.09,"eps":0.994757,"divideRate":0.098588,"volume":68405,"delay":0,"ttmEps":0.994757,"open":10.19,"prevYearClose":9.9,"prevWeekClose":9.75,"prevMonthClose":9.97,"prevQuarterClose":13.17,"fiveDayClose":9.75,"twentyDayClose":10,"sixtyDayClose":10.855},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRT\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521117288","title":"Press Release: CROSS TIMBERS ROYALTY TRUST DECLARES MARCH CASH DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2521117288","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521117288?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:00","pubTimestamp":1742558400,"startTime":"0","endTime":"0","summary":"DALLAS, March 21, 2025 /PRNewswire/ -- Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust  , today declared a cash distribution to the holders of its units of beneficial interest of $0.156725 per unit, payable on April 14, 2025, to unitholders of record on March 31, 2025. The following table shows underlying oil and gas sales and average prices attributable to the current month and prior month distributions.   Sales volumes are recorded in the month the Trust receives. the related net profits income. Because of this, sales. volumes may fluctuate from month to month based on the. XTO Energy has advised the Trustee that excess costs increased by $82,000 on properties underlying the Texas Working Interest net profits interests. However, these excess costs did not reduce net proceeds from the remaining conveyances. Underlying cumulative excess costs remaining on the Texas Working Interest net profits interests total $4,403,000, including accrued interest of $1,195,000.For ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4211","CASH","CRT"],"gpt_icon":0},{"id":"2520570285","title":"AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520570285","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520570285?lang=en_us&edition=fundamental","pubTime":"2025-03-17 23:10","pubTimestamp":1742224200,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi  as monotherapy for treating limited-stage small cell lung cancer  in adult patients whose disease has not progressed following platinum-based chemoradiation therapy .The latest approval for Imfinzi in the European Union  was based on data from the phase III ADRIATIC study.Data from the phase III ADRIATIC study showed that treatment with Imfinzi reduced the risk of death by 27% as compared to placebo. Additionally, treatment with Imfinzi reduced the risk of disease progression or death by 24% versus placebo.The approval in the EU was expected as the Committee for Medicinal Products for Human Use recommended approval of Imfinzi as monotherapy for treating LS-SCLC in adult patients whose disease has not progressed following platinum-based CRT in February 2025.The FDA approved Imfinzi for a similar indication in December 2024.Hypoparathyroidism patients suffer from a deficiency","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azns-imfinzi-gets-eu-nod-151000804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2462157665.USD","IE00B19Z3B42.SGD","SSI","BK4156","LU0889565916.HKD","BK4585","ARVN","BK4007","LU0320765992.SGD","CRT","IE0002270589.USD","LU2456880835.USD","AZN","LU1829250122.USD","BK4213","LU0109394709.USD","BMRN","LU2236285917.USD","BK4588","IE00B7SZLL34.SGD","BK4566","DVAX","BK4568","IE00B19Z3581.USD","LU2417539215.USD","BK4139"],"gpt_icon":0},{"id":"2518287124","title":"SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2518287124","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518287124?lang=en_us&edition=fundamental","pubTime":"2025-03-10 02:00","pubTimestamp":1741543200,"startTime":"0","endTime":"0","summary":"CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trialto primarily enroll women using the two most widely used global TAVR devices. The SMART Trial is an international, prospective, multi-center, randomized (1:1) post-market trial comparing the safety and performance of Evolut self-expanding TAVR versus SAPIEN balloon-expandable TAVR in patients with symptomatic severe aortic stenosis  and small aortic annulus. The trial, the largest head to head randomized control trial to primarily enroll women, randomized and treated 716 patients, 87% of which were women, across more than 80 sites worldwide.2 Eligible patients had an aortic valve annulus area of ≤430 mmas measured by computed tomography, and suitable anatomy for tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/smart-trial-two-data-continues-180000059.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/smart-trial-two-data-continues-180000059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0265550946.USD","AS","IE00BQXX3F31.USD","IE00BFXG1179.USD","IE00BQXX3C00.GBP","LU1571399168.USD","LU2089984988.USD","IE000M9KFDE8.USD","LU1983299246.USD","LU0162691827.USD","BK4533","LU0208291251.USD","LU0211331839.USD","LU0320765489.SGD","LU0976567544.SGD","LU2271345857.HKD","IE00B3T34201.USD","LU2468319806.SGD","LU0211326755.USD","BK4566","BK4202","LU0211326839.USD","LU1291159041.SGD","LU0265550359.USD","LU2028103732.USD","LU1116320901.HKD","LU2111349929.HKD","LU2023251221.USD","LU0496365809.HKD","LU1989764664.SGD","LU0070302665.USD","BK4585","MDT","BK4213","LU0072461881.USD","CRT","LU1989764748.USD","LU2089284900.SGD","BK4082","LU1116320737.USD","LU2089283258.USD","LU0158827781.USD","LU0158827948.USD","BK4588","LU1989771016.USD","IE00BQXX3D17.EUR"],"gpt_icon":0},{"id":"2517482934","title":"IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482934","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482934?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"MATTERHORN is first global, randomized Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over standard of care in this setting. IMFINZI plus chemotherapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023. WILMINGTON, Del., March 07, 2025----Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI  in combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival . Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal j","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-based-regimen-demonstrated-120000536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1829250122.USD","BK4500","LU2456880835.USD","HCC","BTC","BK4144","HSCT","BK4568","LU0320765992.SGD","LU0109394709.USD","LU2462157665.USD","BK4585","BK4213","BK4532","LU2236285917.USD","BK4588","LU2417539215.USD","CRT","BK4124","BK4582","VOD","BK4132","BK4006","BK4156","FLOT","BK4008","OS","BK4007","BK4097","LU0889565916.HKD","TEN","AZN","ALK"],"gpt_icon":0},{"id":"2517438854","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438854","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438854?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348740,"startTime":"0","endTime":"0","summary":"Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib. PRINCETON, N.J., March 07, 2025----Bristol Myers Squibb  today announced that the European Commission  has approved Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .\"The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma,\" said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. \"This approval marks a critical milestone in our commitment to improving outcomes for patients with liver cancer. We look forward to bringing this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-115900243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1261432733.SGD","LU1670711040.USD","BK4532","LU1571399168.USD","LU2125154935.USD","EC","LU2242646821.SGD","LU1032466523.USD","LU1670710588.SGD","IE00B19Z4B17.USD","BK4132","MYE","OS","LU0321505439.SGD","TEN","HCC","RCC","BK4201","AEIS","LU0306807586.USD","IE00BFTCPJ56.SGD","VOD","ORR","BK4581","LU0225284248.USD","LU0114720955.EUR","LU1868836914.USD","LU0306806265.USD","LU1868837136.USD","LU0096364046.USD","LU1291159041.SGD","IE00B7SZL793.SGD","BMY","LU0237698245.USD","ALK","HSCT","LU0321505868.SGD","BK4213","LU1430594728.SGD","BK4157","LU1868836591.USD","BK4124","BK4097","LU0868494617.USD","CRC","LU1868837300.USD","IE00BSNM7G36.USD","CRT","LU0061475181.USD"],"gpt_icon":0},{"id":"2517157883","title":"Press Release: MCCOY GLOBAL ANNOUNCES FOURTH QUARTER AND YEAR END 2024 RESULTS AND INCREASE TO ITS QUARTERLY DIVIDEND","url":"https://stock-news.laohu8.com/highlight/detail?id=2517157883","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517157883?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:18","pubTimestamp":1741267080,"startTime":"0","endTime":"0","summary":"EDMONTON, AB, March 6, 2025 /CNW/ - McCoy Global Inc.   today announced its operational and financial results for the year and three months ended December 31, 2024.-- Revenue increased 28% to $25.2 million, compared to $19.7 million in Q4. 2023, driven by strong demand for recently commercialized smartProducts.smartProduct revenue5 accounted for $12.1 million, or 48%, of total. revenue, an increase of $3.9 million or 48% from Q4 2023.-- Net earnings of $4.3 million, a 59% increase from $2.7 million in 2023.-- Adjusted EBITDA1 increased to $6.5 million, or 26% of revenue, compared. to $4.0 million, or 20% of revenue, in 2023.-- Announced the increase of its quarterly cash dividend to $0.025 per. common share payable on April 15, 2025, to shareholders of record as of. -- Net earnings of $8.9 million, a 36% increase from $6.5 million in 2023.-- Adjusted EBITDA1 of $16.2 million, or 21% of revenue, compared to $13.1. integrated across these mergers. McCoy's FMS is a hydraulic rotary. to in","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","YEAR","BK4588","BK4196","03160","BK4555","TM","BK4099","CRT","FMS","BK4585","BK4604"],"gpt_icon":0},{"id":"2516666515","title":"Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516666515","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516666515?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:05","pubTimestamp":1741035900,"startTime":"0","endTime":"0","summary":"SAN RAFAEL, Calif., March 03, 2025  -- Ekso Bionics Holdings, Inc.  , an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024.Q4-2024 gross margin increased 400 basis points year-over-year to 53%. “We are pleased to close out 2024 with record fourth quarter revenue, improved gross margin and growing interest in our unrivalled portfolio of Enterprise Health and Personal Health devices,” said Scott Davis, the Company’s Chief Executive Officer. “Looking ahead, our focus will be on aggressively executing two key pillars of our growth strategy:  broadening patient access to Ekso Indego Personal and building upon our growing CMS claim pipeline for the device; and  further bolstering demand for our legacy EksoNR device. We look forward to updating investors as we progress.”Research and development expenses for the three months ended December 31, 2024 were $845,000, compared to $1.3 mi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ekso-bionics-reports-fourth-quarter-210500536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","EKSO","BK4082","CRT"],"gpt_icon":0},{"id":"2514381094","title":"Press Release: Robotic Telesurgery Data from Collaboration with Corewell Health(TM) Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2514381094","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514381094?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:30","pubTimestamp":1740490200,"startTime":"0","endTime":"0","summary":"Robotic Telesurgery Data from Collaboration with Corewell Health Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting. Research Collaboration demonstrates the feasibility of using the LIBERTY Endovascular Robotic System between separate and remote facilities in a coronary simulation model. BRAINTREE, Mass., Feb. 25, 2025  -- Microbot Medical Inc. , developer of the innovative LIBERTY Endovascular Robotic System, today announced its collaboration with Corewell Health has reached another meaningful milestone. Under a collaboration agreement, Microbot Medical and Corewell Health are working together to advance robotic telesurgery for endovascular applications. Led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health in Grand Rapids, Michigan, the project assesses the feasibility of using LIBERTY to perform simulated cardiovascular interventional procedures across two sites within the Corewe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4585","CRT","BK4082","BK4099","03160","BK4588","R","BK4232","BK4555","BK4604","TM","BK4213","CSII","MBOT"],"gpt_icon":0},{"id":"2514509829","title":"FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2514509829","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514509829?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:45","pubTimestamp":1740483900,"startTime":"0","endTime":"0","summary":"Acceptance based on results from the KEYNOTE-689 trial: the first Phase 3 trial to demonstrate significant improvement in event-free survival in the neoadjuvant and adjuvant setting for an anti-PD-1 therapy in earlier stages of head and neck squamous cell carcinoma. RAHWAY, N.J., February 25, 2025----Merck , known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration  has accepted for priority review a new supplemental Biologics License Application  seeking approval for KEYTRUDA , Merck’s anti-PD-1 therapy, for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma  as neoadjuvant treatment, then continued as adjuvant treatment in combination with standard of care radiotherapy with or without cisplatin and then as a single agent. The FDA has set a Prescription Drug User Fee Act , or target action, date of June 23, 2025.KEYTRUDA is currently approved as monotherapy and in combination regimens for a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-grants-priority-review-merck-114500312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1929549753.HKD","LU0320765646.SGD","BK4534","LU1989771016.USD","LU0006306889.USD","LU2361045086.USD","LU0238689110.USD","SMP","BK4139","BK4533","LU0265550359.USD","LU0965509101.SGD","LU1037948541.HKD","LU0861579265.USD","CPS","LU1291159041.SGD","IE00BBT3K403.USD","LU1878469433.USD","RCC","LU0265550946.USD","LU2106854487.HKD","BK4585","LU1989772923.USD","HCC","CRC","CRT","LU0456854461.SGD","LU1093756325.SGD","BCG","LU2089984988.USD","SG9999015358.SGD","ALT","IE00B1BXHZ80.USD","HSCT","DM","LU2023250504.SGD","LU1066053197.SGD","LU0122379950.USD","LU1066051225.USD","LU1066051498.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","MRK","AEIS","IE00BLSP4239.USD","LU1116320737.USD","BTC","SG9999002224.SGD","SG9999013999.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2513726307","title":"PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2513726307","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513726307?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"Data confirms Versamune HPV has potential as a broadly effective treatment of HPV16-associated cancers –Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025. Versamune HPV + CRT was associated with greater and earlier clearance of blood-circulating HPV16-positive cancer cells  vs. CRT alone. 100% of patients with locally advanced HPV16 cervical cancer treated with Versamune HPV + CRT had no detectable HPV16 ctDNA at 3-4 months vs. 50% of patients on standard-of-care CRT. Undetectable HPV ctDNA at 3-4 months was associated with improved 2-year recurrence-free survival  of 93% vs only 30% in patients with detectable HPV ctDNA. A total of 66 patients with locally advanced cervical cancer were enrolled, with 49 receiving CRT and 17 receiving a combination of CRT and Versamune HPV. Patient blood was collected at baseline, weeks 1, 3, and 5 of CRT, and 3 to 4 months after CRT to measure HPV ctDNA. MRI was performed at baseline and before brachytherapy to determine tumor sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pds-biotech-announces-circulating-tumor-130000736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRT","BK4213","BK4139","DNA","BK4109","PDS","BK4231","OS","BK4080","ADC","BK4097","PDSB","BK4092"],"gpt_icon":0},{"id":"2513051728","title":"U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...","url":"https://stock-news.laohu8.com/highlight/detail?id=2513051728","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513051728?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:59","pubTimestamp":1740398340,"startTime":"0","endTime":"0","summary":"Application based on analyses from the Phase 3 CheckMate -8HW clinical trial, in which Opdivo plus Yervoy demonstrated superior progression-free survival compared to Opdivo monotherapy and investigator’s choice of chemotherapy. The U.S. Food and Drug Administration assigned a target action date of June 23, 2025. U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer. Opdivo plus Yervoy received approval from the U.S. FDA in July 2018 for the treatment of adult and pediatric patients 12 years and older with MSI-H or dMMR mCRC that have progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan. Opdivo plus Yervoy was also approved in December 2024 in the European Union for the first-line treatment of adult patients with MSI-H or dMMR unresectable or mCRC and in October","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","IE00B2B36J28.USD","BK4008","LU1868836591.USD","LU1868836757.USD","BK4581","LU1291159041.SGD","LU1323610961.USD","LU2242652126.USD","LU1093756168.USD","BK4534","LU0061475181.USD","BK4532","CRT","BK4195","LU2133065610.SGD","BK4559","BK4211","IE0009355771.USD","LU1670710588.SGD","BMY","PFS","BK4144","LU0096364046.USD","LU0985481810.HKD","LU1261432733.SGD","LU0266512127.USD","CRC","ALK","LU1670711123.USD","LU1032466523.USD","BK4126","LU1074936037.SGD","LU0868494617.USD","LU1585245621.USD","LU2360032135.SGD","VOD","IE00BFTCPJ56.SGD","HCC","LU1868837136.USD","LU2125154778.USD","HSCT","BK4585","IE00BJT1NW94.SGD","LU2242646821.SGD","RCC","BK4124","TEN","MYE","LU0882574055.USD"],"gpt_icon":0},{"id":"2512915404","title":"CROSS TIMBERS ROYALTY TRUST DECLARES FEBRUARY CASH DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2512915404","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512915404?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883600,"startTime":"0","endTime":"0","summary":"DALLAS, Feb. 18, 2025 /PRNewswire/ -- Argent Trust Company, as Trustee of the Cross Timbers Royalty Trust  , today declared a cash distribution to the holders of its units of beneficial interest of $0.045553 per unit, payable on March 14, 2025, to unitholders of record on February 28, 2025. The following table shows underlying oil and gas sales and average prices attributable to the current month and prior month distributions. Sales volumes are recorded in the month the Trust receives the related net profits income.   Because of this, sales volumes may fluctuate from month to month based on the timing of   cash receipts.Excess Costs      XTO Energy has advised the Trustee that excess costs increased by $9,000 on properties underlying the Texas Working Interest net profits interests. However, these excess costs did not reduce net proceeds from the remaining conveyances. Underlying cumulative excess costs remaining on the Texas Working Interest net profits interests total $4,296,000, inc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cross-timbers-royalty-trust-declares-130000897.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cross-timbers-royalty-trust-declares-130000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","CASH","CRT","BK4211"],"gpt_icon":0},{"id":"2511684789","title":"AGNC Investment Corp. (AGNC): Among the Best Stocks That Pay Monthly Dividends in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2511684789","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511684789?lang=en_us&edition=fundamental","pubTime":"2025-02-14 11:13","pubTimestamp":1739502793,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Stocks That Pay Monthly Dividends in 2025.In this article, we are going to take a look at where AGNC Investment Corp.  stands against the other dividend stocks.The majority of dividend-paying stocks distribute payouts on a quarterly basis, or every three months. However, companies that provide dividends on a monthly schedule are much less common. Those that do typically prioritize rewarding shareholders and offer a consistent income stream.Real estate investment trusts  are among the few that pay monthly dividends. These investment vehicles trade like stocks, allowing investors to gain exposure to large-scale commercial real estate projects. To maintain their tax-advantaged status, REITs are required to distribute at least 90% of their taxable income to shareholders, which exempts them from corporate income tax. In general, REITs provide attractive yields, portfolio diversification, and liquidity while also serving as a defensive investment op","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agnc-investment-corp-agnc-among-031313344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","CRT","NQmain","NVIW.SI","AGNCP","AGNCL","AGNCM","QLD","BK4110","BK4588","BK4585","AGNCN","QID","REIT","USAW.SI","TQQQ","AGNC","AGNCO","BK4213",".IXIC","PSQ","USJW.SI","MNQmain","TSYW.SI"],"gpt_icon":1},{"id":"2510856174","title":"NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry","url":"https://stock-news.laohu8.com/highlight/detail?id=2510856174","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510856174?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:00","pubTimestamp":1739188800,"startTime":"0","endTime":"0","summary":"Move expected to broaden access to Ekso Bionics’ portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United StatesSAN RAFAEL, Calif., ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/10/3023296/29945/en/NSM-Named-Exclusive-Distributor-of-Ekso-Indego-Personal-Within-the-CRT-Industry.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRT","BK4213"],"gpt_icon":0},{"id":"2509953304","title":"Biocurious: EBR Systems is on a ‘glide path’ to FDA approval for its novel heart device","url":"https://stock-news.laohu8.com/highlight/detail?id=2509953304","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509953304?lang=en_us&edition=fundamental","pubTime":"2025-02-05 04:00","pubTimestamp":1738699219,"startTime":"0","endTime":"0","summary":"The US regulator is due to decide on approving EBR’s Wise leadless pacemaker on or before April 13. The company is preparing to enter the US$3.6 billion US market with a targeted approach. EBR’s expanded Silicon Valley manufacturing hub protects the company from Trump’s tariffs","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-186543442-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/GettyImages-186543442-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/uncategorized/biocurious-ebr-systems-is-on-a-glide-path-to-fda-approval-for-its-novel-heart-device/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["IE00B1B80R65.USD","EBR","BK4213","CRT","BK4081"],"gpt_icon":0},{"id":"2509644462","title":"CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2509644462","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509644462?lang=en_us&edition=fundamental","pubTime":"2025-02-05 00:07","pubTimestamp":1738685220,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ announced that the European Medicines Agency’s  Committee for Medicinal Products for Human Use  rendered a positive opinion for the expanded use of the subcutaneous  formulation of Rybrevant  in advanced EGFR-mutated non-small cell lung cancer .The CHMP recommendation is for SC Rybrevant in combination with Lazcluze  for the first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletion  or L858R mutation. The CHMP also recommended marketing authorization for the SC formulation of Rybrevant as a monotherapy for treating adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy.The European Commission had approved a combination of its intravenously administered Rybrevant plus Lazcluze for a similar use in Europe in December 2024.In the past year, shares of J&J have lost 2.5% compared with the industry’s decline of 2.6%.CHMP Nod to JNJ's Rybrevant Based on Data From PALOMA-3 Study. Im","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chmp-gives-nod-expanded-j-160700577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1674673691.USD","LU2347655156.SGD","BK4087","PK","LU2089984988.USD","SG9999002224.SGD","LU0912757837.SGD","LU2112291526.USD","IE00BJJMRZ35.SGD","LU0203347892.USD","AZN","IE00B7SZLL34.SGD","IE00BGHQF631.EUR","LU0234572021.USD","LU1914381329.SGD","HRMY","LU1244550577.SGD","LU0889566641.SGD","LU0889565916.HKD","LU1162221912.USD","LU0795875169.SGD","BK4181","LU1061106388.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0002270589.USD","BK4213","LU0345769128.USD","LU1023059063.AUD","LU1059921491.USD","LU1585245621.USD","IE00BSNM7G36.USD","LU1066053197.SGD","IE0009355771.USD","LU1261432733.SGD","JNJ","BK4533","BMRN","CHMP","LU2505996509.AUD","BK4581","CRT","LU0466842654.USD","BK4139","LU2417539215.USD","IE0034235303.USD","BK4585","BK4534","LU0320765646.SGD"],"gpt_icon":0},{"id":"2507061378","title":"Is AGNC Investment Corp. (AGNC) the Best Monthly Dividend Stock to Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2507061378","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507061378?lang=en_us&edition=fundamental","pubTime":"2025-01-30 13:30","pubTimestamp":1738215026,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 15 Best Monthly Dividend Stocks To Buy Right Now.In this article, we are going to take a look at where AGNC Investment Corp.  stands against the other monthly dividend stocks.8 Best Value Dividend Stocks to Invest in According to Warren Buffett. Analysts point out that dividend growth has historically been closely tied to earnings performance. With strong earnings growth in 2024, they expect an even better showing in 2025. Goldman projects an 11% rise in earnings per share this year, up from an estimated 8% last year, which is likely to drive a 7% increase in dividends, compared to a 6% bump in 2024. Meanwhile, Kwon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agnc-investment-corp-agnc-best-053026259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","TSYW.SI","BK4213","USJW.SI","QID","AGNCP","BK4110","CRT","SQQQ","BK4588","QLD","TQQQ","AGNCO","MNQmain","AGNCM","AGNCL","BK4585","USAW.SI","AGNCN","AGNC","REIT","PSQ","NQmain",".IXIC"],"gpt_icon":1},{"id":"2506580851","title":"Enact Mortgage Insurance Enters into Two Forward XOL Reinsurance Transactions as Part of its Diversified Credit Risk Transfer Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2506580851","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506580851?lang=en_us&edition=fundamental","pubTime":"2025-01-28 05:15","pubTimestamp":1738012500,"startTime":"0","endTime":"0","summary":"Secures approximately $225 million and $260 million of excess of loss reinsurance coverage from a panel of third-party reinsurance providersRALEIGH, N.C., Jan.  27, 2025  (GLOBE NEWSWIRE) -- Enact Hol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/27/3015986/0/en/Enact-Mortgage-Insurance-Enters-into-Two-Forward-XOL-Reinsurance-Transactions-as-Part-of-its-Diversified-Credit-Risk-Transfer-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FORD","BK4202","BK4213","CRT"],"gpt_icon":0},{"id":"2506988385","title":"AGNC Investment Corp. (AGNC): Why You Should Invest In This Extreme Dividend Stock Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2506988385","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506988385?lang=en_us&edition=fundamental","pubTime":"2025-01-26 08:55","pubTimestamp":1737852906,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Extreme Dividend Stocks to Invest in Now.In this article, we are going to take a look at where AGNC Investment Corp.  stands against the other dividend stocks.In 2024, dividend stocks underperformed the broader market as attention shifted to high-flying tech stocks. The Dividend Aristocrat index, which tracks companies with a minimum of 25 consecutive years of dividend growth, rose only 6.3% compared to the broader market's impressive 27% gain. Despite this, analysts remain positive about the long-term outlook for dividend stocks, as they have historically delivered stronger performance over extended periods.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agnc-investment-corp-agnc-why-005506199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","AGNCM","MNQmain","AGNCO","TSYW.SI","AGNCN","SQQQ","TQQQ","AGNC","US2Y.BOND","US30Y.BOND","BK4110","US3Y.BOND","US10Y.BOND","QID","BK4588","AGNCP","USJW.SI","NVIW.SI","BK4213",".IXIC","US7Y.BOND","US5Y.BOND","QLD","US12M.BOND","AGNCL","NQmain","CRT","PSQ","BK4585","US6M.BOND"],"gpt_icon":1},{"id":"2505718573","title":"Analysts’ Opinions Are Mixed on These Real Estate Stocks: Aena SA (GB:0R4Y), Assura plc (GB:AGR) and Impact Healthcare REIT (GB:CRT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505718573","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505718573?lang=en_us&edition=fundamental","pubTime":"2025-01-22 17:01","pubTimestamp":1737536473,"startTime":"0","endTime":"0","summary":"Companies in the Real Estate sector have received a lot of coverage today as analysts weigh in on Aena SA (GB:0R4Y – Research Report), Assura plc (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-real-estate-stocks-aena-sa-gb0r4y-assura-plc-gbagr-and-impact-healthcare-reit-gbcrt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-real-estate-stocks-aena-sa-gb0r4y-assura-plc-gbagr-and-impact-healthcare-reit-gbcrt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGR","BK4081","BK4213","BK4225","BK4137","HCSG","BK4203","GB","BK4106","REIT","BK4227","ARSSF","CRT"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRT\",params:#limit:5,,,undefined,":[{"date":"2025-05-30","symbol":"CRT","amount":0.0808,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-30","defaultRemindTime":1748611800000,"name":"CRT信托","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-13","payableDate":"2025-05-30","currency":"USD","dateTimestamp":1748577600000,"payDate":"2025-06-13"},{"market":"US","date":"2025-05-14","symbol":"CRT","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"","actualEps":0.3},{"date":"2025-04-30","symbol":"CRT","amount":0.03211,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-30","defaultRemindTime":1746019800000,"name":"CRT信托","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-14","payableDate":"2025-04-30","currency":"USD","dateTimestamp":1745985600000,"payDate":"2025-05-14"},{"date":"2025-03-31","symbol":"CRT","amount":0.156725,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"CRT信托","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-14","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-14"},{"market":"US","date":"2025-03-27","symbol":"CRT","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRT\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-26","recordDate":"2015-06-30","paymentDate":"2015-07-14","value":0.080113,"currency":"USD"},{"executeDate":"2015-07-29","recordDate":"2015-07-31","paymentDate":"2015-08-14","value":0.099748,"currency":"USD"},{"executeDate":"2015-08-27","recordDate":"2015-08-31","paymentDate":"2015-09-15","value":0.099341,"currency":"USD"},{"executeDate":"2015-09-28","recordDate":"2015-09-30","paymentDate":"2015-10-15","value":0.094355,"currency":"USD"},{"executeDate":"2015-10-28","recordDate":"2015-10-30","paymentDate":"2015-11-16","value":0.102382,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRT","date":"2025-06-13","current":10.082864,"percent":0.484947,"low":5.93557,"twenty":8.44973,"median":10.1767,"eighty":14.103137,"high":20.651413,"avg":11.084661,"sd":3.316408,"marketCap":60180000},"quantilePoints":[{"date":"2020-06-19","current":7.270743,"twenty":6.621907,"median":9.067856,"eighty":12.467109,"marketCap":43500000},{"date":"2020-06-26","current":7.361001,"twenty":6.672159,"median":9.067856,"eighty":12.467109,"marketCap":44040000},{"date":"2020-07-02","current":7.1504,"twenty":6.699118,"median":9.067856,"eighty":12.467109,"marketCap":42780000},{"date":"2020-07-10","current":6.689084,"twenty":6.710103,"median":9.067856,"eighty":12.467109,"marketCap":40020000},{"date":"2020-07-17","current":6.187653,"twenty":6.710103,"median":9.067856,"eighty":12.467109,"marketCap":37020000},{"date":"2020-07-24","current":6.614672,"twenty":6.710103,"median":9.067856,"eighty":12.467109,"marketCap":39574800},{"date":"2020-07-31","current":6.232782,"twenty":6.710103,"median":9.067856,"eighty":12.467109,"marketCap":37290000},{"date":"2020-08-07","current":6.368168,"twenty":6.710103,"median":9.067856,"eighty":12.467109,"marketCap":38100000},{"date":"2020-08-14","current":6.860703,"twenty":6.757678,"median":9.067856,"eighty":12.467109,"marketCap":36855600},{"date":"2020-08-21","current":6.768447,"twenty":6.771178,"median":9.067856,"eighty":12.467109,"marketCap":36360000},{"date":"2020-08-28","current":7.159363,"twenty":6.810956,"median":9.067856,"eighty":12.467109,"marketCap":38460000},{"date":"2020-09-04","current":6.835461,"twenty":6.821019,"median":9.067856,"eighty":12.467109,"marketCap":36720000},{"date":"2020-09-11","current":6.857799,"twenty":6.835587,"median":9.067856,"eighty":12.467109,"marketCap":36840000},{"date":"2020-09-18","current":6.768223,"twenty":6.858116,"median":9.067856,"eighty":12.467109,"marketCap":36358800},{"date":"2020-09-25","current":6.48922,"twenty":6.858116,"median":9.067856,"eighty":12.467109,"marketCap":34860000},{"date":"2020-10-02","current":6.098303,"twenty":6.858116,"median":9.067856,"eighty":12.467109,"marketCap":32760000},{"date":"2020-10-09","current":6.243278,"twenty":6.838644,"median":9.067856,"eighty":12.467109,"marketCap":33538800},{"date":"2020-10-16","current":6.511558,"twenty":6.835587,"median":9.067856,"eighty":12.467109,"marketCap":34980000},{"date":"2020-10-23","current":7.349237,"twenty":6.858116,"median":9.067856,"eighty":12.467109,"marketCap":39480000},{"date":"2020-10-30","current":8.209254,"twenty":6.878433,"median":9.067856,"eighty":12.467109,"marketCap":44100000},{"date":"2020-11-06","current":9.244814,"twenty":6.902826,"median":9.074987,"eighty":12.467109,"marketCap":44940000},{"date":"2020-11-13","current":10.330987,"twenty":6.924813,"median":9.120614,"eighty":12.467109,"marketCap":50220000},{"date":"2020-11-20","current":9.911329,"twenty":6.945184,"median":9.150702,"eighty":12.467109,"marketCap":48180000},{"date":"2020-11-27","current":10.232244,"twenty":6.96358,"median":9.162951,"eighty":12.467109,"marketCap":49740000},{"date":"2020-12-04","current":9.627443,"twenty":6.990733,"median":9.188359,"eighty":12.467109,"marketCap":46800000},{"date":"2020-12-11","current":9.849614,"twenty":7.015283,"median":9.202046,"eighty":12.467109,"marketCap":47880000},{"date":"2020-12-18","current":10.368015,"twenty":7.04534,"median":9.226016,"eighty":12.467109,"marketCap":50400000},{"date":"2020-12-24","current":10.491444,"twenty":7.072885,"median":9.248611,"eighty":12.467109,"marketCap":51000000},{"date":"2020-12-31","current":10.170529,"twenty":7.087866,"median":9.262892,"eighty":12.467109,"marketCap":49440000},{"date":"2021-01-08","current":10.392701,"twenty":7.129213,"median":9.27535,"eighty":12.467109,"marketCap":50520000},{"date":"2021-01-15","current":10.195215,"twenty":7.152193,"median":9.286268,"eighty":12.467109,"marketCap":49560000},{"date":"2021-01-22","current":10.244586,"twenty":7.172744,"median":9.299784,"eighty":12.467109,"marketCap":49800000},{"date":"2021-01-29","current":9.504014,"twenty":7.214589,"median":9.338988,"eighty":12.467109,"marketCap":46200000},{"date":"2021-02-05","current":10.021057,"twenty":7.229231,"median":9.355899,"eighty":12.467109,"marketCap":48713400},{"date":"2021-02-12","current":10.151027,"twenty":7.250221,"median":9.371894,"eighty":12.467109,"marketCap":49345200},{"date":"2021-02-19","current":11.096245,"twenty":7.270743,"median":9.409785,"eighty":12.467109,"marketCap":53940000},{"date":"2021-02-26","current":10.923445,"twenty":7.292398,"median":9.441362,"eighty":12.467109,"marketCap":53100000},{"date":"2021-03-05","current":11.355445,"twenty":7.34712,"median":9.497564,"eighty":12.468828,"marketCap":55200000},{"date":"2021-03-12","current":12.453961,"twenty":7.361001,"median":9.566299,"eighty":12.482371,"marketCap":60540000},{"date":"2021-03-19","current":11.269045,"twenty":7.408933,"median":9.622888,"eighty":12.482371,"marketCap":54780000},{"date":"2021-03-26","current":10.68893,"twenty":7.423035,"median":9.639786,"eighty":12.479662,"marketCap":51960000},{"date":"2021-04-01","current":10.60253,"twenty":7.49369,"median":9.656657,"eighty":12.479662,"marketCap":51540000},{"date":"2021-04-09","current":11.071559,"twenty":7.531804,"median":9.703447,"eighty":12.482371,"marketCap":53820000},{"date":"2021-04-16","current":11.140889,"twenty":7.556966,"median":9.750871,"eighty":12.482371,"marketCap":52080000},{"date":"2021-04-23","current":12.180534,"twenty":7.571602,"median":9.766899,"eighty":12.482371,"marketCap":56940000},{"date":"2021-04-30","current":12.616928,"twenty":7.615202,"median":9.806414,"eighty":12.494608,"marketCap":58980000},{"date":"2021-05-07","current":13.078992,"twenty":7.682222,"median":9.841907,"eighty":12.503201,"marketCap":61140000},{"date":"2021-05-14","current":15.610404,"twenty":7.717157,"median":9.883983,"eighty":12.526935,"marketCap":60960000},{"date":"2021-05-21","current":15.164831,"twenty":7.782203,"median":9.913169,"eighty":12.536097,"marketCap":59220000},{"date":"2021-05-28","current":14.965092,"twenty":7.824611,"median":9.944313,"eighty":12.546167,"marketCap":58440000},{"date":"2021-06-04","current":15.287748,"twenty":7.872851,"median":9.971976,"eighty":12.563354,"marketCap":59700000},{"date":"2021-06-11","current":15.441393,"twenty":7.880546,"median":9.985386,"eighty":12.571947,"marketCap":60300000},{"date":"2021-06-18","current":15.56431,"twenty":7.893169,"median":10.010072,"eighty":12.587481,"marketCap":60780000},{"date":"2021-06-25","current":18.667953,"twenty":7.939412,"median":10.034758,"eighty":12.598778,"marketCap":72900000},{"date":"2021-07-02","current":17.223684,"twenty":7.951639,"median":10.096472,"eighty":12.615118,"marketCap":67260000},{"date":"2021-07-09","current":17.607798,"twenty":7.960357,"median":10.108815,"eighty":12.630808,"marketCap":68760000},{"date":"2021-07-16","current":17.377329,"twenty":7.960357,"median":10.145843,"eighty":12.639613,"marketCap":67860000},{"date":"2021-07-23","current":19.174984,"twenty":7.98167,"median":10.167447,"eighty":12.659667,"marketCap":74880000},{"date":"2021-07-30","current":18.775505,"twenty":7.995539,"median":10.182872,"eighty":12.68366,"marketCap":73320000},{"date":"2021-08-06","current":17.822902,"twenty":8.009454,"median":10.199165,"eighty":12.711966,"marketCap":69600000},{"date":"2021-08-13","current":16.150292,"twenty":8.009454,"median":10.234666,"eighty":12.756936,"marketCap":72120000},{"date":"2021-08-20","current":15.263504,"twenty":8.009454,"median":10.256929,"eighty":12.783365,"marketCap":68160000},{"date":"2021-08-27","current":16.365271,"twenty":8.009454,"median":10.287786,"eighty":12.818164,"marketCap":73080000},{"date":"2021-09-03","current":16.926634,"twenty":8.009454,"median":10.331402,"eighty":12.833711,"marketCap":75586800},{"date":"2021-09-10","current":16.123419,"twenty":8.009454,"median":10.374187,"eighty":12.854872,"marketCap":72000000},{"date":"2021-09-17","current":17.440165,"twenty":8.009454,"median":10.417731,"eighty":12.882425,"marketCap":77880000},{"date":"2021-09-24","current":19.240614,"twenty":8.009454,"median":10.504955,"eighty":12.917553,"marketCap":85920000},{"date":"2021-10-01","current":19.106252,"twenty":8.009454,"median":10.583661,"eighty":12.944662,"marketCap":85320000},{"date":"2021-10-08","current":20.651413,"twenty":8.009454,"median":10.62548,"eighty":12.95853,"marketCap":92220000},{"date":"2021-10-15","current":20.328945,"twenty":8.009454,"median":10.662788,"eighty":12.983815,"marketCap":90780000},{"date":"2021-10-22","current":18.461315,"twenty":8.009454,"median":10.691788,"eighty":13.049275,"marketCap":82440000},{"date":"2021-10-29","current":18.434443,"twenty":8.009707,"median":10.732305,"eighty":13.08048,"marketCap":82320000},{"date":"2021-11-05","current":19.227178,"twenty":8.009707,"median":10.742312,"eighty":13.162363,"marketCap":85860000},{"date":"2021-11-12","current":13.602537,"twenty":8.009707,"median":10.792834,"eighty":13.230652,"marketCap":83700000},{"date":"2021-11-19","current":11.067297,"twenty":8.009707,"median":10.807619,"eighty":13.238255,"marketCap":68100000},{"date":"2021-11-26","current":11.896125,"twenty":8.009707,"median":10.807619,"eighty":13.238255,"marketCap":73200000},{"date":"2021-12-03","current":9.750922,"twenty":8.009707,"median":10.807619,"eighty":13.238255,"marketCap":60000000},{"date":"2021-12-10","current":10.696762,"twenty":8.009707,"median":10.739836,"eighty":13.238255,"marketCap":65820000},{"date":"2021-12-17","current":10.277472,"twenty":8.009707,"median":10.717242,"eighty":13.238255,"marketCap":63240000},{"date":"2021-12-23","current":11.31107,"twenty":8.009707,"median":10.717242,"eighty":13.238255,"marketCap":69600000},{"date":"2021-12-31","current":11.174557,"twenty":8.009707,"median":10.717242,"eighty":13.238255,"marketCap":68760000},{"date":"2022-01-07","current":11.769363,"twenty":8.009961,"median":10.721601,"eighty":13.234818,"marketCap":72420000},{"date":"2022-01-14","current":13.066236,"twenty":8.009961,"median":10.721601,"eighty":13.234818,"marketCap":80400000},{"date":"2022-01-21","current":13.10524,"twenty":8.009961,"median":10.721601,"eighty":13.258494,"marketCap":80640000},{"date":"2022-01-28","current":13.446522,"twenty":8.009961,"median":10.721601,"eighty":13.281823,"marketCap":82740000},{"date":"2022-02-04","current":14.528874,"twenty":8.009961,"median":10.721601,"eighty":13.31505,"marketCap":89400000},{"date":"2022-02-11","current":14.558127,"twenty":8.009961,"median":10.736902,"eighty":13.338305,"marketCap":89580000},{"date":"2022-02-18","current":14.236347,"twenty":8.009961,"median":10.749664,"eighty":13.393471,"marketCap":87600000},{"date":"2022-02-25","current":14.894534,"twenty":8.009961,"median":10.830284,"eighty":13.417826,"marketCap":91650000},{"date":"2022-03-04","current":15.484465,"twenty":8.009961,"median":10.946951,"eighty":13.471216,"marketCap":95280000},{"date":"2022-03-11","current":15.845249,"twenty":8.009961,"median":10.986766,"eighty":13.51972,"marketCap":97500000},{"date":"2022-03-18","current":14.314354,"twenty":8.009961,"median":11.077731,"eighty":13.580741,"marketCap":88080000},{"date":"2022-03-25","current":13.573284,"twenty":8.009961,"median":11.122435,"eighty":13.603533,"marketCap":83520000},{"date":"2022-04-01","current":11.814241,"twenty":8.009961,"median":11.145616,"eighty":13.603533,"marketCap":78840000},{"date":"2022-04-08","current":12.092964,"twenty":8.009961,"median":11.211742,"eighty":13.603533,"marketCap":80700000},{"date":"2022-04-14","current":12.362695,"twenty":8.009961,"median":11.256702,"eighty":13.603533,"marketCap":82500000},{"date":"2022-04-22","current":13.369693,"twenty":8.009961,"median":11.319498,"eighty":13.614314,"marketCap":89220000},{"date":"2022-04-29","current":13.468595,"twenty":8.009961,"median":11.352759,"eighty":13.641654,"marketCap":89880000},{"date":"2022-05-06","current":14.250816,"twenty":8.009961,"median":11.413684,"eighty":13.675545,"marketCap":95100000},{"date":"2022-05-13","current":12.993784,"twenty":8.009961,"median":11.413684,"eighty":13.70999,"marketCap":95100000},{"date":"2022-05-20","current":15.010485,"twenty":8.009961,"median":11.413684,"eighty":13.753017,"marketCap":109860000},{"date":"2022-05-27","current":15.641729,"twenty":8.009961,"median":11.413684,"eighty":13.801264,"marketCap":114480000},{"date":"2022-06-03","current":14.567795,"twenty":8.009961,"median":11.413684,"eighty":13.826646,"marketCap":106620000},{"date":"2022-06-10","current":15.79749,"twenty":8.009961,"median":11.413684,"eighty":13.873668,"marketCap":115620000},{"date":"2022-06-17","current":14.297262,"twenty":8.009961,"median":11.413684,"eighty":13.874468,"marketCap":104640000},{"date":"2022-06-24","current":14.059521,"twenty":8.009707,"median":11.410988,"eighty":13.897974,"marketCap":102900000},{"date":"2022-07-01","current":12.387134,"twenty":8.009707,"median":11.410988,"eighty":13.933076,"marketCap":90660000},{"date":"2022-07-08","current":11.928048,"twenty":8.009707,"median":11.398828,"eighty":13.933076,"marketCap":87300000},{"date":"2022-07-15","current":13.059368,"twenty":8.009707,"median":11.398828,"eighty":13.933076,"marketCap":95580000},{"date":"2022-07-22","current":13.993937,"twenty":8.009707,"median":11.398828,"eighty":13.954875,"marketCap":102420000},{"date":"2022-07-29","current":15.010485,"twenty":8.009707,"median":11.398828,"eighty":13.979654,"marketCap":109860000},{"date":"2022-08-05","current":14.567795,"twenty":8.009707,"median":11.398828,"eighty":14.001242,"marketCap":106620000},{"date":"2022-08-12","current":12.549381,"twenty":8.009707,"median":11.398828,"eighty":14.029636,"marketCap":115560000},{"date":"2022-08-19","current":12.823044,"twenty":8.009707,"median":11.398828,"eighty":14.029636,"marketCap":118080000},{"date":"2022-08-26","current":14.72565,"twenty":8.009707,"median":11.398828,"eighty":14.055815,"marketCap":135600000},{"date":"2022-09-02","current":13.298695,"twenty":8.009707,"median":11.398828,"eighty":14.084883,"marketCap":122460000},{"date":"2022-09-09","current":14.09362,"twenty":8.009707,"median":11.398828,"eighty":14.09169,"marketCap":129780000},{"date":"2022-09-16","current":14.393346,"twenty":8.009707,"median":11.398828,"eighty":14.141203,"marketCap":132540000},{"date":"2022-09-23","current":11.500342,"twenty":8.009707,"median":11.398828,"eighty":14.141203,"marketCap":105900000},{"date":"2022-09-30","current":12.575445,"twenty":8.009707,"median":11.355445,"eighty":14.141203,"marketCap":115800000},{"date":"2022-10-07","current":15.051439,"twenty":8.009707,"median":11.355445,"eighty":14.215272,"marketCap":138600000},{"date":"2022-10-14","current":13.865568,"twenty":8.009707,"median":11.355445,"eighty":14.215272,"marketCap":127680000},{"date":"2022-10-21","current":14.764745,"twenty":8.009707,"median":11.355445,"eighty":14.245895,"marketCap":135960000},{"date":"2022-10-28","current":15.038407,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":138480000},{"date":"2022-11-04","current":13.318243,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":122640000},{"date":"2022-11-11","current":14.080588,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":129660000},{"date":"2022-11-18","current":11.855702,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":126180000},{"date":"2022-11-25","current":12.566029,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":133740000},{"date":"2022-12-02","current":14.048697,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":149520000},{"date":"2022-12-09","current":12.340529,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":131340000},{"date":"2022-12-16","current":12.374354,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":131700000},{"date":"2022-12-23","current":14.116347,"twenty":8.009707,"median":11.355445,"eighty":14.280469,"marketCap":150240000},{"date":"2022-12-30","current":14.341848,"twenty":8.009707,"median":11.355445,"eighty":14.300488,"marketCap":152640000},{"date":"2023-01-06","current":13.394745,"twenty":8.009707,"median":11.355445,"eighty":14.298116,"marketCap":142560000},{"date":"2023-01-13","current":13.930309,"twenty":8.009707,"median":11.355445,"eighty":14.255346,"marketCap":148260000},{"date":"2023-01-20","current":14.392586,"twenty":8.009707,"median":11.355445,"eighty":14.237759,"marketCap":153180000},{"date":"2023-01-27","current":15.142376,"twenty":8.009707,"median":11.355445,"eighty":14.237759,"marketCap":161160000},{"date":"2023-02-03","current":14.747749,"twenty":8.009707,"median":11.355445,"eighty":14.255346,"marketCap":156960000},{"date":"2023-02-10","current":15.531364,"twenty":8.009707,"median":11.355445,"eighty":14.299207,"marketCap":165300000},{"date":"2023-02-17","current":15.046538,"twenty":8.009707,"median":11.355445,"eighty":14.346809,"marketCap":160140000},{"date":"2023-02-24","current":11.461076,"twenty":8.009707,"median":11.355445,"eighty":14.307017,"marketCap":121980000},{"date":"2023-03-03","current":10.637998,"twenty":8.009707,"median":11.330572,"eighty":14.275418,"marketCap":113220000},{"date":"2023-03-10","current":9.08768,"twenty":8.009707,"median":11.297163,"eighty":14.263524,"marketCap":96720000},{"date":"2023-03-17","current":7.616288,"twenty":8.006501,"median":11.244359,"eighty":14.219343,"marketCap":81060000},{"date":"2023-03-24","current":9.335731,"twenty":7.99797,"median":11.166559,"eighty":14.118602,"marketCap":99360000},{"date":"2023-03-31","current":9.554436,"twenty":8.000401,"median":11.139946,"eighty":14.077625,"marketCap":112200000},{"date":"2023-04-06","current":9.83034,"twenty":8.000401,"median":11.112498,"eighty":14.050862,"marketCap":115440000},{"date":"2023-04-14","current":10.004057,"twenty":7.995539,"median":11.084934,"eighty":14.055191,"marketCap":117480000},{"date":"2023-04-21","current":10.893079,"twenty":7.995539,"median":10.989993,"eighty":14.055191,"marketCap":127920000},{"date":"2023-04-28","current":10.673378,"twenty":7.995539,"median":10.986766,"eighty":14.055191,"marketCap":125340000},{"date":"2023-05-05","current":10.305507,"twenty":7.993108,"median":10.958248,"eighty":14.057356,"marketCap":121020000},{"date":"2023-05-12","current":10.770455,"twenty":7.993108,"median":10.852808,"eighty":14.057356,"marketCap":126480000},{"date":"2023-05-19","current":8.852709,"twenty":7.993108,"median":10.807619,"eighty":14.057356,"marketCap":121260000},{"date":"2023-05-26","current":9.299506,"twenty":7.993108,"median":10.746539,"eighty":14.057356,"marketCap":127380000},{"date":"2023-06-02","current":9.10677,"twenty":7.993108,"median":10.725959,"eighty":14.057356,"marketCap":124740000},{"date":"2023-06-09","current":10.469062,"twenty":7.993108,"median":10.694647,"eighty":14.057356,"marketCap":143400000},{"date":"2023-06-16","current":11.1743,"twenty":7.993108,"median":10.679585,"eighty":14.057356,"marketCap":153060000},{"date":"2023-06-23","current":9.553567,"twenty":7.990677,"median":10.672528,"eighty":14.059521,"marketCap":130860000},{"date":"2023-06-30","current":9.908376,"twenty":7.990677,"median":10.622285,"eighty":14.062431,"marketCap":135720000},{"date":"2023-07-07","current":9.281984,"twenty":7.990677,"median":10.565501,"eighty":14.062431,"marketCap":127140000},{"date":"2023-07-14","current":8.440955,"twenty":7.990677,"median":10.513893,"eighty":14.062431,"marketCap":115620000},{"date":"2023-07-21","current":8.546084,"twenty":7.990677,"median":10.454415,"eighty":14.062431,"marketCap":117060000},{"date":"2023-07-28","current":9.067347,"twenty":7.990677,"median":10.39339,"eighty":14.062431,"marketCap":124200000},{"date":"2023-08-04","current":9.067347,"twenty":7.990677,"median":10.373035,"eighty":14.062431,"marketCap":124200000},{"date":"2023-08-11","current":8.953457,"twenty":7.990677,"median":10.355733,"eighty":14.062431,"marketCap":122640000},{"date":"2023-08-18","current":9.683499,"twenty":7.990677,"median":10.316476,"eighty":14.062431,"marketCap":127620000},{"date":"2023-08-25","current":9.159944,"twenty":7.990677,"median":10.269272,"eighty":14.062431,"marketCap":120720000},{"date":"2023-09-01","current":9.455867,"twenty":7.990677,"median":10.241637,"eighty":14.065342,"marketCap":124620000},{"date":"2023-09-08","current":9.264655,"twenty":7.990677,"median":10.22431,"eighty":14.065342,"marketCap":122100000},{"date":"2023-09-15","current":10.289003,"twenty":7.990677,"median":10.191603,"eighty":14.065342,"marketCap":135600000},{"date":"2023-09-22","current":8.909548,"twenty":7.990677,"median":10.170529,"eighty":14.065342,"marketCap":117420000},{"date":"2023-09-29","current":9.146286,"twenty":7.990677,"median":10.152227,"eighty":14.065342,"marketCap":120540000},{"date":"2023-10-06","current":8.39965,"twenty":7.990677,"median":10.143374,"eighty":14.065342,"marketCap":110700000},{"date":"2023-10-13","current":8.581757,"twenty":7.990677,"median":10.10424,"eighty":14.065342,"marketCap":113100000},{"date":"2023-10-20","current":8.404203,"twenty":7.990677,"median":10.055124,"eighty":14.065342,"marketCap":110760000},{"date":"2023-10-27","current":8.135596,"twenty":7.990677,"median":10.034758,"eighty":14.074073,"marketCap":107220000},{"date":"2023-11-03","current":8.422414,"twenty":7.990677,"median":10.010072,"eighty":14.074073,"marketCap":111000000},{"date":"2023-11-10","current":8.24486,"twenty":7.990677,"median":9.985386,"eighty":14.074073,"marketCap":108660000},{"date":"2023-11-17","current":9.372752,"twenty":7.990677,"median":9.962963,"eighty":14.074073,"marketCap":111480000},{"date":"2023-11-24","current":10.184923,"twenty":7.990677,"median":9.948357,"eighty":14.074073,"marketCap":121140000},{"date":"2023-12-01","current":9.468598,"twenty":7.990677,"median":9.932561,"eighty":14.074073,"marketCap":112620000},{"date":"2023-12-08","current":9.519044,"twenty":7.990677,"median":9.911329,"eighty":14.071163,"marketCap":113220000},{"date":"2023-12-15","current":9.100347,"twenty":7.990677,"median":9.884038,"eighty":14.071163,"marketCap":108240000},{"date":"2023-12-22","current":9.266817,"twenty":7.990677,"median":9.870083,"eighty":14.071163,"marketCap":110220000},{"date":"2023-12-29","current":8.974234,"twenty":7.990677,"median":9.871214,"eighty":14.074073,"marketCap":106740000},{"date":"2024-01-05","current":8.933877,"twenty":7.990091,"median":9.876268,"eighty":14.074635,"marketCap":106260000},{"date":"2024-01-12","current":8.827942,"twenty":7.990091,"median":9.876268,"eighty":14.074635,"marketCap":105000000},{"date":"2024-01-19","current":8.550492,"twenty":7.989505,"median":9.868953,"eighty":14.075197,"marketCap":101700000},{"date":"2024-01-26","current":9.12557,"twenty":7.990091,"median":9.862382,"eighty":14.074635,"marketCap":108540000},{"date":"2024-02-02","current":9.01459,"twenty":7.990091,"median":9.862382,"eighty":14.074635,"marketCap":107220000},{"date":"2024-02-09","current":8.653098,"twenty":7.990091,"median":9.862382,"eighty":14.074635,"marketCap":102920400},{"date":"2024-02-16","current":8.807764,"twenty":7.990091,"median":9.862382,"eighty":14.074635,"marketCap":104760000},{"date":"2024-02-23","current":8.752274,"twenty":7.990091,"median":9.862382,"eighty":14.074635,"marketCap":104100000},{"date":"2024-03-01","current":8.621116,"twenty":7.990677,"median":9.855812,"eighty":14.074073,"marketCap":102540000},{"date":"2024-03-08","current":8.460195,"twenty":7.990677,"median":9.855812,"eighty":14.074073,"marketCap":100626000},{"date":"2024-03-15","current":8.716962,"twenty":7.990677,"median":9.855812,"eighty":14.074073,"marketCap":103680000},{"date":"2024-03-22","current":6.366207,"twenty":7.967059,"median":9.855812,"eighty":14.074073,"marketCap":75720000},{"date":"2024-03-28","current":6.608345,"twenty":7.950304,"median":9.855812,"eighty":14.074073,"marketCap":78600000},{"date":"2024-04-05","current":7.138968,"twenty":7.941228,"median":9.862382,"eighty":14.074635,"marketCap":82440000},{"date":"2024-04-12","current":6.910355,"twenty":7.889973,"median":9.862382,"eighty":14.074635,"marketCap":79800000},{"date":"2024-04-19","current":6.827222,"twenty":7.844425,"median":9.862382,"eighty":14.074635,"marketCap":78840000},{"date":"2024-04-26","current":7.502671,"twenty":7.795306,"median":9.855812,"eighty":14.074073,"marketCap":86640000},{"date":"2024-05-03","current":6.894767,"twenty":7.726926,"median":9.855812,"eighty":14.074073,"marketCap":79620000},{"date":"2024-05-10","current":7.149359,"twenty":7.682222,"median":9.855812,"eighty":14.074073,"marketCap":82560000},{"date":"2024-05-17","current":8.966269,"twenty":7.640335,"median":9.83829,"eighty":14.074073,"marketCap":84300000},{"date":"2024-05-24","current":8.729508,"twenty":7.640335,"median":9.831805,"eighty":14.074073,"marketCap":82074000},{"date":"2024-05-31","current":9.135384,"twenty":7.640335,"median":9.831805,"eighty":14.074073,"marketCap":85890000},{"date":"2024-06-07","current":8.570604,"twenty":7.640335,"median":9.831805,"eighty":14.074073,"marketCap":80580000},{"date":"2024-06-14","current":8.398299,"twenty":7.638623,"median":9.834885,"eighty":14.074635,"marketCap":78960000},{"date":"2024-06-21","current":6.892221,"twenty":7.624059,"median":9.837965,"eighty":14.075197,"marketCap":64800000},{"date":"2024-06-28","current":6.707152,"twenty":7.615202,"median":9.831072,"eighty":14.076884,"marketCap":63060000},{"date":"2024-07-05","current":6.209381,"twenty":7.583787,"median":9.797365,"eighty":14.076884,"marketCap":58380000},{"date":"2024-07-12","current":6.05622,"twenty":7.549432,"median":9.790107,"eighty":14.076884,"marketCap":56940000},{"date":"2024-07-15","current":6.566755,"twenty":7.541516,"median":9.790107,"eighty":14.076884,"marketCap":61740000},{"date":"2024-08-02","current":6.483793,"twenty":7.526694,"median":9.849614,"eighty":14.097348,"marketCap":60960000},{"date":"2024-08-09","current":6.362541,"twenty":7.500185,"median":9.849614,"eighty":14.097348,"marketCap":59820000},{"date":"2024-08-16","current":8.330038,"twenty":7.484922,"median":9.849614,"eighty":14.097348,"marketCap":64200000},{"date":"2024-08-23","current":7.921321,"twenty":7.484922,"median":9.849614,"eighty":14.097348,"marketCap":61050000},{"date":"2024-08-30","current":7.699446,"twenty":7.484922,"median":9.849614,"eighty":14.097348,"marketCap":59340000},{"date":"2024-09-06","current":7.119457,"twenty":7.435611,"median":9.849614,"eighty":14.097348,"marketCap":54870000},{"date":"2024-09-13","current":7.15449,"twenty":7.407031,"median":9.849614,"eighty":14.097348,"marketCap":55140000},{"date":"2024-09-20","current":7.240126,"twenty":7.361001,"median":9.849614,"eighty":14.097348,"marketCap":55800000},{"date":"2024-09-27","current":8.080915,"twenty":7.361001,"median":9.849614,"eighty":14.097348,"marketCap":62280000},{"date":"2024-10-04","current":8.392318,"twenty":7.407031,"median":9.849614,"eighty":14.097348,"marketCap":64680000},{"date":"2024-10-11","current":8.115948,"twenty":7.435611,"median":9.849614,"eighty":14.097348,"marketCap":62550000},{"date":"2024-10-18","current":8.610301,"twenty":7.490676,"median":9.849614,"eighty":14.097348,"marketCap":66360000},{"date":"2024-10-25","current":8.485739,"twenty":7.521459,"median":9.849614,"eighty":14.097348,"marketCap":65400000},{"date":"2024-10-31","current":8.174336,"twenty":7.534577,"median":9.849614,"eighty":14.097348,"marketCap":63000000},{"date":"2024-11-08","current":7.715016,"twenty":7.56266,"median":9.849614,"eighty":14.098591,"marketCap":59460000},{"date":"2024-11-15","current":8.879894,"twenty":7.56266,"median":9.849614,"eighty":14.098591,"marketCap":60180000},{"date":"2024-11-22","current":9.827201,"twenty":7.56266,"median":9.849614,"eighty":14.098591,"marketCap":66600000},{"date":"2024-11-29","current":9.685547,"twenty":7.56266,"median":9.849614,"eighty":14.098591,"marketCap":65640000},{"date":"2024-12-06","current":8.959574,"twenty":7.56266,"median":9.849614,"eighty":14.098591,"marketCap":60720000},{"date":"2024-12-13","current":8.986134,"twenty":7.586268,"median":9.849614,"eighty":14.098591,"marketCap":60900000},{"date":"2024-12-20","current":8.277867,"twenty":7.640637,"median":9.849614,"eighty":14.098591,"marketCap":56100000},{"date":"2024-12-27","current":8.764801,"twenty":7.70256,"median":9.849614,"eighty":14.098591,"marketCap":59400000},{"date":"2025-01-03","current":8.844481,"twenty":7.70256,"median":9.849614,"eighty":14.098591,"marketCap":59940000},{"date":"2025-01-10","current":8.729387,"twenty":7.699446,"median":9.849614,"eighty":14.099834,"marketCap":59160000},{"date":"2025-01-17","current":9.145494,"twenty":7.699446,"median":9.849614,"eighty":14.099834,"marketCap":61980000},{"date":"2025-01-24","current":9.836054,"twenty":7.699446,"median":9.849614,"eighty":14.099834,"marketCap":66660000},{"date":"2025-01-31","current":9.473067,"twenty":7.699446,"median":9.849614,"eighty":14.099834,"marketCap":64200000},{"date":"2025-02-07","current":9.402241,"twenty":7.715016,"median":9.849614,"eighty":14.099834,"marketCap":63720000},{"date":"2025-02-14","current":9.366827,"twenty":7.715016,"median":9.849614,"eighty":14.099834,"marketCap":63480000},{"date":"2025-02-21","current":9.729814,"twenty":7.715016,"median":9.855812,"eighty":14.099834,"marketCap":65940000},{"date":"2025-02-28","current":9.579307,"twenty":7.715016,"median":9.855812,"eighty":14.099834,"marketCap":64920000},{"date":"2025-03-07","current":9.437654,"twenty":7.811551,"median":9.862382,"eighty":14.103137,"marketCap":63960000},{"date":"2025-03-14","current":9.517334,"twenty":7.856705,"median":9.862382,"eighty":14.103137,"marketCap":64500000},{"date":"2025-03-21","current":9.836054,"twenty":7.920558,"median":9.862382,"eighty":14.103137,"marketCap":66660000},{"date":"2025-03-28","current":12.427309,"twenty":7.995093,"median":9.897835,"eighty":14.103137,"marketCap":70560000},{"date":"2025-04-04","current":12.532984,"twenty":8.041719,"median":9.940527,"eighty":14.103137,"marketCap":71160000},{"date":"2025-04-11","current":10.778789,"twenty":8.097564,"median":9.977707,"eighty":14.099834,"marketCap":61200000},{"date":"2025-04-17","current":11.465672,"twenty":8.121938,"median":10.010072,"eighty":14.099834,"marketCap":65100000},{"date":"2025-04-25","current":10.736519,"twenty":8.165725,"median":10.052751,"eighty":14.103137,"marketCap":60960000},{"date":"2025-05-02","current":10.683682,"twenty":8.206941,"median":10.102643,"eighty":14.103137,"marketCap":60660000},{"date":"2025-05-09","current":10.662547,"twenty":8.277402,"median":10.141401,"eighty":14.103137,"marketCap":60540000},{"date":"2025-05-16","current":10.052706,"twenty":8.346918,"median":10.148867,"eighty":14.103137,"marketCap":60000000},{"date":"2025-05-23","current":10.273866,"twenty":8.382072,"median":10.162866,"eighty":14.103137,"marketCap":61320000},{"date":"2025-05-30","current":10.113023,"twenty":8.39938,"median":10.1767,"eighty":14.103137,"marketCap":60360000},{"date":"2025-06-06","current":9.801389,"twenty":8.419509,"median":10.1767,"eighty":14.103137,"marketCap":58500000},{"date":"2025-06-13","current":10.082864,"twenty":8.44973,"median":10.1767,"eighty":14.103137,"marketCap":60180000}],"updateTime":1750024166136}}}